Patricia Allen will be presenting this topic at Cheshire Medical Center/Dartmouth Hitchcock Kenne on Tuesday, January 31 at 11:00am to nurses, clinicians and social workers. The goal is to educate providers on how to identify best practices that support engagement and recovery for those suffering from the disease of addiction. Participants of this presentation will learn how to review the genetic test and will be given techniques on how to utilize this data in counseling their patients and in forming continuing care plans. This presentation will use case studies which demonstrate the clinical value of pharmacogenetic testing, its impact on clinical outcomes for clients with co-occurring disorders, and reduces the stigma that is a barrier to treatment.
Summit Behavior Health believes clients with co-occurring disorders benefit from client-centered care that offers personalized treatment. The benefits of pharmacogenetics testing are evident in clients' engagement and response to treatment. Patricia recently presented this topic at Holy Family Hospital at Merrimack in Haverhill, MA with an overwhelmingly positive response.
Summit Behavioral Health offers intensive outpatient, partial care, medical detox and residential programs for substance abuse treatment that is tailored to each individual's needs. By blending some of the best clinical practices and evidence-based strategies available, Summit Behavioral Health's programs treat both addiction and its underlying causes.
Summit Behavioral Health provides a solid foundation for recovery and improves the overall quality of life for individuals with substance abuse disorders and related mental health problems using an integrative treatment approach.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/serenity-at-summit-new-england-presents-on-the-clinical-application-of-pharmacogenetic-testing-300398771.html
SOURCE Summit Behavioral Health